Member Info for andyrp

If true then the current vaccines being developed are not the long term solution unless administered every few months. However, they might provide a bit of a circuit break to coin a current phrase. What this does mean though is that therapeutic approaches are going to be needed for a long time if immunity doesn’t exist.

It’s the very fact that such an opportunity like this exists that I more than doubled my holding here this morning.

Positive results from Phase II , current SP, general COVID state of play, lack of immunity, vaccine availability is uncertain, vaccine doubters, vaccine efficacy, potential emergency approval prior to conclusion of phase III.

Don’t forget this is not just about improved patient outcomes, in the UK at least it will offer a significant reduction in pressure on the NHS if recovery can be improved and beds freed up.

I sold out of NCYT yesterday, I held on 3 separate occasions making 65%, 25% and 25% profit - nowhere near as some others but better than the bank bound offer me.

I looked here after the placing so now holding and hope you are right that this is the next big one. Looking at the lack of immunity it’s going to take testing and treatment to keep the nation safe so I feel treatment is where the next big rises are going to be found.

General upwards trend, how high will it go by the end of today, end of the month end of the year? Broker indicates blue sky SP of >£30!

This is good news for SNG then as the trial looked at subcutaneous administration and not nebuliser inhalation. The use of a nebuliser ensures the drug is delivered to the target area reducing the first stages of drug metabolism and ensuring higher levels of efficacy.

There are 2 vaccines in the running for administration via a mass vaccination program between December 2020 and August 2021 but likely to be delayed given EMA said approval will be Q1 2021. Mass vaccination program for UK is not using the AZ vaccine.

These are not people on huge CEO level salaries, they have potentially found themselves with new liabilities due to the phenomenal growth of the company and no free cash to cover those liabilities.

NCYT buy IT-IS for £10.1 million but IT-IS have £3.6 million of cash on the balance sheet; therefore real cost to NCYT is £6.5 million. GM has struck a fantastic deal!!!!!!!!!

NCYT have time and time again demonstrated they are the market leader. They are first to market with innovative solutions and I don't think there is another diagnostics company out there that has the scale, expertise, reputation, or market share that NCYT has. Oh and don't forget - GOLD STANDARD!!!!!!!!!

Let's hope so as I have just joined the party at 193p!

We need some consolidation and to build a new price. With the increases every day we’ve created a bit of a gap which has now been filled. We will now continue increase from the stability of this new base.

https://youtu.be/hOMvs_1UFCk

We only have 20,000 odd care homes who would really be benefit from this point of care testing capability! Massive opportunity.

It's going up yet he said it's going back down - has he got his chart upside down!

.....and then on to an even higher SP. This is a fantastic share to be part of and I get the feel that the company really values and appreciates the support of PIs.

Roche don’t do the logistics; it’s outsourced.

The distribution concerns have escalated to the MHRA!

Those charts look like witchcraft to me, I can’t claim to understand them but I’m happy with what it is showing - as an interim to an even bigger share price that is.